Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

MRK

Merck & Co Inc

May 21 • 02:39PM ET

130.63

Dollar change -0.36
Percentage change -0.28	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO IVV VTV VIG VYM VHT IWD DGRO HDV

Index	DJIA, S&P 500	P/E	145.42	EPS (ttm)	0.90	Insider Own	0.12%	Shs Outstand	2.53B	Perf Week	1.53%
Market Cap	330.86B	Forward P/E	13.15	EPS next Y	9.94	Insider Trans	-11.88%	Shs Float	2.53B	Perf Month	2.91%
Income	2.31B	PEG	-	EPS next Q	2.14	Inst Own	79.11%	Short Float	0.74%	Perf Quarter	1.96%
Sales	61.09B	P/S	5.42	EPS this Y	473.14%	Inst Trans	0.64%	Short Ratio	2.29	Perf Half Y	28.38%
Book/sh	15.94	P/B	8.20	EPS next Y	14.80%	ROA	2.16%	Short Interest	18.75M	Perf Year	13.11%
Cash/sh	2.25	P/C	57.93	EPS next 5Y	-	ROE	5.29%	52W Range	99.14 - 133.10	Perf YTD	19.82%
Dividend Est.	3.16 (2.42%)	P/FCF	29.97	EPS past 5Y	-42.70%	ROI	3.22%	52W High	-1.86%	Beta	0.41
Dividend TTM	3.00 (2.30%)	Quick Ratio	0.99	Sales past 5Y	7.72%	Gross Margin	71.63%	52W Low	31.76%	ATR (14)	1.91
Dividend Ex-Date	Mar 14, 2024	Current Ratio	1.25	EPS Y/Y TTM	-82.24%	Oper. Margin	8.23%	RSI (14)	56.97	Volatility	1.24% 1.48%
Employees	72000	Debt/Eq	0.85	Sales Y/Y TTM	7.01%	Profit Margin	3.77%	Recom	1.52	Target Price	144.01
Option/Short	Yes / Yes	LT Debt/Eq	0.77	EPS Q/Q	69.28%	Payout	2065.60%	Rel Volume	0.43	Prev Close	130.99
Sales Surprise	3.75%	EPS Surprise	9.79%	Sales Q/Q	8.38%	Earnings	Apr 25 BMO	Avg Volume	8.19M	Price	130.63
SMA20	0.86%	SMA50	2.65%	SMA200	13.65%	Trades		Volume	2,844,351	Change	-0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115
Mar-06-23	Initiated	Jefferies	Buy	$125
Feb-22-23	Upgrade	Wolfe Research	Peer Perform → Outperform	$127
Jan-04-23	Upgrade	BofA Securities	Neutral → Buy	$110 → $130
Nov-18-22	Initiated	Credit Suisse	Outperform	$120
Oct-10-22	Upgrade	Guggenheim	Neutral → Buy
Sep-14-22	Upgrade	Berenberg	Hold → Buy	$95 → $100
Jul-06-22	Upgrade	Daiwa Securities	Neutral → Buy	$89 → $102
Jun-06-22	Resumed	SVB Leerink	Outperform	$102
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$80
Dec-17-21	Initiated	Goldman	Buy	$93
Dec-16-21	Initiated	Daiwa Securities	Neutral	$70

Show Previous Ratings

May-20-24 09:14AM	Here's Why Merck (MRK) Stock Has Outperformed Industry YTD (Zacks)
May-17-24 06:00AM	Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches (InvestorPlace)
May-16-24 10:51AM	Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game (Benzinga)
09:35AM	Merck (MRK) Crossed Above the 20-Day Moving Average: What That Means for Investors (Zacks)
May-15-24 06:45AM	Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline (Business Wire)
09:25AM	Loading…
May-14-24 09:25AM	Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility (Zacks)
05:21AM	Merck cancels trial of melanoma treatment due to immune-mediated adverse events (Clinical Trials Arena)
May-13-24 01:09PM	Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment (Benzinga)
06:45AM	Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma (Business Wire)
May-10-24 06:30AM	3 Biotech Stocks to Sell in May Before They Crash & Burn (InvestorPlace)
06:01AM	The 3 Most Undervalued Healthcare Stocks to Buy in May 2024 (InvestorPlace)
May-09-24 09:00AM	Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know (Zacks)
07:05AM	Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy (PR Newswire)
06:45AM	Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent (Business Wire)
May-08-24 09:15AM	Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers (ACCESSWIRE)
08:30AM	Loading…
08:30AM	Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024 (GlobeNewswire)
06:56AM	Q1 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
06:45AM	Merck to Participate in the Bank of America Securities 2024 Healthcare Conference (Business Wire)
May-07-24 02:49PM	5 Best S&P 500 Dividend Stocks To Buy Now (Insider Monkey)
May-06-24 02:30PM	3 Biotech Stocks to Double Your Money in the Next 24 Months (InvestorPlace)
10:50AM	5 Best Recession Dividend Stocks To Buy (Insider Monkey)
08:11AM	Gossamer sells rights to drug it hopes can rival a new Merck therapy (BioPharma Dive)
May-03-24 09:50AM	Here's Why Merck (MRK) is a Strong Momentum Stock (Zacks)
May-02-24 02:53PM	Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration (Benzinga)
May-01-24 06:52PM	15 Best Places to Retire in Florida That You've Never Heard Of (Insider Monkey)
07:15AM	Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (Business Wire)
06:24AM	3 Pharma Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace)
Apr-30-24 08:44AM	Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-29-24 09:00AM	Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults (Business Wire)
Apr-28-24 06:54PM	Dividend Stock Portfolio For Income: Top 5 Stocks (Insider Monkey)
09:14AM	Loading…
Apr-27-24 09:14AM	5 Best Long Term Low Risk Stocks to Buy (Insider Monkey)
Apr-26-24 10:59AM	Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128 (MT Newswires)
Apr-25-24 05:54PM	5 Best Growth Stocks To Invest In For the Next 5 Years (Insider Monkey)
04:09PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
03:30PM	Merck (MRK) Q1 2024 Earnings Call Transcript (Motley Fool)
02:29PM	Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook (Benzinga)
12:52PM	Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating (MT Newswires)
12:09PM	Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales (Zacks)
11:42AM	Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma (The Wall Street Journal)
11:34AM	20 Fastest Growing Health Tech Companies in the World (Insider Monkey)
11:23AM	Merck raises 2024 guidance on cancer drug demand (Yahoo Finance Video)
10:54AM	MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:30AM	Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:13AM	Merck Stock Climbs After Higher-Than-Expected Sales of Cancer Drug Keytruda (The Wall Street Journal)
09:13AM	Merck Shares Climb After Higher-Than-Expected Sales of Cancer Drug Keytruda (The Wall Street Journal)
07:30AM	Stocks plunge on weaker-than-expected GDP reading: Yahoo Finance (Yahoo Finance Video)
07:04AM	UPDATE 3-Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda (Reuters)
06:44AM	Merck: Q1 Earnings Snapshot (Associated Press Finance)
06:33AM	Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda (Reuters)
06:30AM	Merck raises 2024 profit forecast on strong cancer, HPV drugs sales (Reuters)
06:30AM	Merck Announces First-Quarter 2024 Financial Results (Business Wire)
Apr-24-24 05:50PM	Alphabet, Microsoft, Southwest earnings: What to watch (Yahoo Finance Video)
Apr-23-24 07:49AM	Here's Why Merck & Co. (MRK) Outperformed in Q1 (Insider Monkey)
Apr-22-24 02:39PM	How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings? (Zacks)
11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
09:15AM	Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS (Zacks)
Apr-21-24 10:49AM	11 Hot Growth Stocks To Buy Right Now (Insider Monkey)
Apr-19-24 07:04AM	Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy (PR Newswire)
Apr-18-24 04:27PM	13 Best Low Volatility Stocks to Buy According to Hedge Funds (Insider Monkey)
10:01AM	Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-17-24 05:50PM	Merck (MRK) Advances While Market Declines: Some Information for Investors (Zacks)
08:00AM	Coming FDA Approvals Could Send These 3 Drug Stocks Soaring (InvestorPlace)
Apr-16-24 03:17PM	3 Dow Stocks to Buy Now: Q2 Edition (InvestorPlace)
Apr-15-24 07:48AM	10 Best Low Volatility ETFs To Buy (Insider Monkey)
Apr-12-24 06:40AM	7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 (InvestorPlace)
Apr-11-24 05:50PM	Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Apr-08-24 11:38PM	Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised) (Zacks)
02:00PM	Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement (InvestorPlace)
Apr-07-24 02:00PM	The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024 (InvestorPlace)
Apr-06-24 08:47PM	10 Best Weight Loss Drug Stocks to Buy Now (Insider Monkey)
Apr-05-24 05:45PM	Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
05:33AM	Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate (Zacks)
Apr-04-24 07:38AM	Merck puts KRAS cancer drug competitor to the test (BioPharma Dive)
06:45AM	Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer (Business Wire)
05:36AM	Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Zacks)
Apr-03-24 05:50PM	Merck (MRK) Stock Sinks As Market Gains: What You Should Know (Zacks)
08:00AM	REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Apr-01-24 09:50AM	Why Merck (MRK) is a Top Momentum Stock for the Long-Term (Zacks)
06:45AM	Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25 (Business Wire)
Mar-29-24 10:51AM	3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List (InvestorPlace)
Mar-28-24 05:50PM	Merck (MRK) Rises Higher Than Market: Key Facts (Zacks)
09:15AM	How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together (ACCESSWIRE)
06:45AM	European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults (Business Wire)
Mar-27-24 04:36PM	US STOCKS-Stocks close with gains, led by Dow as investors look for rate insight (Reuters)
04:00PM	US STOCKS-Stocks gain, led by Dow as investors look for rate insight (Reuters)
02:58PM	US STOCKS-Dow leads gains on Wall Street as investors await rate clues (Reuters)
12:20PM	US STOCKS-Dow outperforms Wall Street in thin trading week (Reuters)
11:54AM	Merck Stock Hits Record High as FDA Approves Its Cardiovascular Disease Drug (Investopedia)
10:58AM	FDA approves Merck treatment for lung disease, potential path to upside (Yahoo Finance Video)
10:26AM	Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck (The Wall Street Journal)
10:10AM	US STOCKS-Dow leads Wall St higher in lean trading week (Reuters)
09:53AM	Merck Drug for Rare Form of High Blood Pressure Gets US Nod (Bloomberg)
09:00AM	Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock (Zacks)
08:50AM	US STOCKS-Wall St set to open higher as growth stocks recover (Reuters)
08:39AM	Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair (Zacks)
07:36AM	US STOCKS-Futures tick up in thin trading week, Fed commentary in focus (Reuters)
07:36AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Mar-26-24 06:21PM	FDA Approves Mercks WINREVAIR (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) (Business Wire)
05:07PM	Mercks $11.5 Billion Bet on Its Next Big Drug Finally Arrives (The Wall Street Journal)
01:12PM	FDA approves Merck lung disease drug acquired in $11B deal (BioPharma Dive)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 04 '24	Option Exercise	127.51	27,126	3,458,836	163,720	May 06 04:08 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 04 '24	Option Exercise	127.51	912	116,289	24,271	May 06 04:01 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 04 '24	Option Exercise	127.51	887	113,101	24,058	May 06 04:06 PM
Smart Dalton	SVP Fin. - Global Controller	May 04 '24	Option Exercise	127.51	612	78,036	4,730	May 06 04:10 PM
Smart Dalton	SVP Fin. - Global Controller	May 03 '24	Option Exercise	128.26	2,046	262,420	4,708	May 06 04:10 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '24	Option Exercise	128.80	2,262	291,346	21,831	May 02 04:29 PM
Smart Dalton	SVP Fin. - Global Controller	May 02 '24	Option Exercise	128.80	381	49,073	3,048	May 02 04:23 PM
Merck & Co., Inc.	10% Owner	Mar 11 '24	Buy	23.00	21,397,205	492,135,715	1,000	Mar 11 03:27 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Option Exercise	73.73	85,021	6,268,598	433,348	Feb 15 04:01 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Option Exercise	58.08	38,291	2,223,941	89,199	Feb 15 04:03 PM
Davis Robert M	Chairman, CEO & President	Feb 14 '24	Sale	125.40	85,021	10,661,574	348,327	Feb 15 04:01 PM
Litchfield Caroline	EVP & CFO	Feb 14 '24	Sale	125.50	38,291	4,805,520	50,908	Feb 15 04:03 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Option Exercise	74.18	150,000	11,127,160	498,327	Feb 15 04:01 PM
Davis Robert M	Chairman, CEO & President	Feb 13 '24	Sale	125.85	150,000	18,877,424	348,327	Feb 15 04:01 PM
Romanelli Joseph	President, Human Health Int?l	Feb 13 '24	Sale	124.89	1,000	124,888	19,569	Feb 14 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Option Exercise	62.07	14,702	912,553	60,944	Feb 12 04:03 PM
Li Dean Y	Executive VP & President, MRL	Feb 09 '24	Sale	125.50	14,702	1,845,083	46,242	Feb 12 04:03 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 07 '24	Sale	127.57	1,451	185,108	19,812	Feb 08 04:04 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Option Exercise	73.65	32,994	2,430,159	74,313	Feb 02 04:07 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Option Exercise	87.10	19,417	1,691,221	78,557	Feb 02 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Option Exercise	78.80	20,937	1,649,906	42,286	Feb 05 04:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 02 '24	Sale	126.65	50,694	6,420,349	23,619	Feb 02 04:07 PM
Zachary Jennifer	EVP, General Counsel	Feb 02 '24	Sale	126.97	49,499	6,284,779	29,058	Feb 02 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 02 '24	Sale	127.17	18,959	2,411,111	23,327	Feb 05 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Nov 09 '23	Sale	102.38	2,081	213,061	18,191	Nov 13 07:36 AM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Nov 08 '23	Sale	105.03	43,823	4,602,668	111,764	Nov 09 09:04 AM
Oosthuizen Johannes Jacobus	President, U.S. Market	Oct 30 '23	Option Exercise	102.82	915	94,080	20,723	Oct 31 11:08 AM
MIZELL STEVEN	EVP, Chief HR Officer	Aug 14 '23	Sale	109.01	4,250	463,292	22,935	Aug 15 04:08 PM
Guindo Chirfi	Chief Marketing Officer	Aug 03 '23	Option Exercise	105.70	36,901	3,900,436	38,342	Aug 04 04:17 PM
MIZELL STEVEN	EVP, Chief HR Officer	Aug 03 '23	Sale	105.49	4,500	474,701	27,185	Aug 04 04:06 PM
Romanelli Joseph	President, Human Health Int?l	Aug 02 '23	Sale	107.37	59	6,335	0	Aug 03 04:08 PM
Romanelli Joseph	President, Human Health Int?l	Aug 02 '23	Sale	107.37	30	3,221	20,569	Aug 03 04:08 PM

Open in Screener

RXRX

Recursion Pharmaceuticals Inc

May 21 • 02:39PM ET

9.53

Dollar change -0.24
Percentage change -2.51	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

RXRX Recursion Pharmaceuticals Inc daily Stock Chart

Held by: ARKK ARKG VTI VB IWM VBK VXF IWN IBB SCHA

Index	RUT	P/E	-	EPS (ttm)	-1.60	Insider Own	22.27%	Shs Outstand	226.26M	Perf Week	-5.12%
Market Cap	2.26B	Forward P/E	-	EPS next Y	-1.82	Insider Trans	-2.03%	Shs Float	162.21M	Perf Month	25.46%
Income	-354.11M	PEG	-	EPS next Q	-0.41	Inst Own	71.60%	Short Float	24.97%	Perf Quarter	-22.92%
Sales	46.23M	P/S	48.99	EPS this Y	-5.93%	Inst Trans	4.55%	Short Ratio	6.60	Perf Half Y	35.25%
Book/sh	1.64	P/B	5.82	EPS next Y	-8.96%	ROA	-59.75%	Short Interest	40.50M	Perf Year	48.29%
Cash/sh	1.26	P/C	7.56	EPS next 5Y	12.00%	ROE	-85.19%	52W Range	4.97 - 16.75	Perf YTD	-3.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-43.41%	ROI	-79.40%	52W High	-43.06%	Beta	0.95
Dividend TTM	-	Quick Ratio	4.65	Sales past 5Y	132.77%	Gross Margin	-36.92%	52W Low	91.85%	ATR (14)	0.66
Dividend Ex-Date	-	Current Ratio	4.65	EPS Y/Y TTM	-16.02%	Oper. Margin	-836.46%	RSI (14)	56.27	Volatility	7.36% 7.13%
Employees	-	Debt/Eq	0.13	Sales Y/Y TTM	-0.88%	Profit Margin	-765.90%	Recom	2.43	Target Price	13.00
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	-13.55%	Payout	-	Rel Volume	0.41	Prev Close	9.78
Sales Surprise	21.54%	EPS Surprise	7.87%	Sales Q/Q	13.68%	Earnings	May 09 AMC	Avg Volume	6.14M	Price	9.53
SMA20	8.72%	SMA50	3.98%	SMA200	6.39%	Trades		Volume	2,035,245	Change	-2.51%

Date	Action	Analyst	Rating Change	Price Target Change
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

May-17-24 02:36AM	Director Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com)
May-15-24 08:45AM	What's the Difference Between Biotech Stocks and TechBio Stocks? (Motley Fool)
May-13-24 09:59AM	Recursion Pharmaceuticals Says BioHive-2 AI Supercomputer Completed (MT Newswires) +10.23%
05:00AM	Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry (GlobeNewswire)
May-12-24 08:15AM	Cathie Wood Is Buying This Under-the-Radar AI Stock (Motley Fool)
08:05PM	Loading…
May-10-24 08:05PM	Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer (CNBC TV)
01:26PM	Recursion Pharmaceuticals Inc (RXRX) Q1 2024 Earnings: Revenue Surpasses Estimates Amid ... (GuruFocus.com)
12:36PM	Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:59PM	RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:04PM	Recursion Pharmaceuticals Q1 Loss Widens, Revenue Rises (MT Newswires)
05:25PM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:32PM	Recursion Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 11:41AM	Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? (Zacks)
May-03-24 05:50PM	Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
09:00AM	Loading…
May-02-24 09:00AM	Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know (Zacks) +5.40%
08:00AM	Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9 (GlobeNewswire)
May-01-24 08:01AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.65%
Apr-30-24 08:00AM	Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program (GlobeNewswire)
07:29AM	Jim Cramer is Recommending These 10 Stocks Heading Into May 2024 (Insider Monkey)
Apr-27-24 08:58AM	Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves (Motley Fool)
07:00AM	The Top 3 Biotech Stocks to Buy in April 2024 (InvestorPlace)
Apr-25-24 05:50PM	Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors (Zacks)
10:30AM	3 Millionaire-Maker Biotech Stocks (Motley Fool)
08:01AM	AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029 (PR Newswire)
Apr-17-24 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks)
07:00AM	Where Will Recursion Pharmaceuticals Be in 5 Years? (Motley Fool)
Apr-16-24 08:00AM	Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer (GlobeNewswire)
Apr-15-24 12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace) -7.37%
08:00AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
05:50AM	Loading…
Apr-10-24 05:50AM	Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. (Motley Fool) -5.61%
Apr-08-24 09:00AM	The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation (Motley Fool)
Apr-04-24 08:45AM	Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy? (Motley Fool)
01:31AM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares (GuruFocus.com)
Apr-03-24 09:35AM	Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround (Zacks)
Apr-02-24 08:00AM	Recursion to Participate in Upcoming Investor Conference (GlobeNewswire) -6.40%
Apr-01-24 12:00PM	All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy (Zacks) -6.02%
Mar-26-24 08:00AM	Recursion Publishes Annual Environmental, Social and Governance Report (GlobeNewswire)
Mar-22-24 01:29AM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares (GuruFocus.com)
Mar-18-24 01:00PM	New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence (Benzinga)
Mar-15-24 04:54PM	Since Nvidia Disclosed Stakes in These Stocks, They've Soared (Investopedia)
01:49AM	Recursion Pharmaceuticals Inc CFO Michael Secora Sells 50,000 Shares (GuruFocus.com)
Mar-11-24 04:00AM	Recursion Announces Plans to Open New Office in London (GlobeNewswire) -7.33%
Mar-07-24 10:28AM	Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-01-24 02:58PM	Recursion Hosts Second Annual Rare Disease Day Events for Utah's Rare Disease Community (GlobeNewswire)
02:00PM	Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? (InvestorPlace)
07:59AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-28-24 06:44PM	Why Recursion Pharmaceuticals Stock Dived by Nearly 17% Today (Motley Fool) -16.62%
10:56AM	Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 06:35PM	Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.15%
05:42PM	Recursion Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:34PM	Recursion Pharmaceuticals Inc (RXRX) Reports Mixed Financial Results Amidst Advancements in ... (GuruFocus.com)
04:05PM	Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results (GlobeNewswire)
Feb-24-24 03:08AM	Recursion Pharmaceuticals Inc President and COO Tina Marriott Sells 8,000 Shares (GuruFocus.com)
Feb-22-24 09:37AM	These 2 Healthcare Stocks Are in Nvidia's Portfolio. Should They Be in Yours? (Motley Fool) +21.26%
Feb-21-24 11:27PM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares (GuruFocus.com)
Feb-20-24 07:59AM	Recursion to Host Public L(earnings) Call on February 27 (GlobeNewswire)
Feb-19-24 05:13PM	Double Your Money: 3 Growth Stocks to Grab in 2024 (InvestorPlace)
10:00AM	Analysts Estimate Recursion Pharmaceuticals (RXRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:00AM	Investors Are Piling Into Nvidia Stock. But Nvidia Is Investing in 5 Other AI Stocks. (Motley Fool)
Feb-18-24 09:00AM	Get Rich Quick With These 3 AI Stocks to Buy Now (InvestorPlace)
Feb-16-24 10:50AM	The Nvidia stock surge is now extending to other companies (Quartz) +5.79%
02:53AM	Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? (Zacks)
Feb-15-24 06:27PM	Why Recursion Pharmaceuticals Stock Zoomed Higher on Thursday (Motley Fool) +13.83%
04:17PM	Nvidia Discloses Stakes In Arm, SoundHound AI, Nano-X And More (Investor's Business Daily)
03:46PM	Nvidia bets on AI future with new investments, shares rally (Yahoo Finance Video)
03:17PM	Nvidia's investments in these AI companies sent their stocks soaring (Yahoo Finance)
Feb-10-24 02:58AM	Recursion Pharmaceuticals Inc CEO Christopher Gibson Sells 48,272 Shares (GuruFocus.com)
Feb-09-24 02:23AM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares (GuruFocus.com)
Feb-08-24 10:30AM	2 Cathie Wood Stocks With Jaw-Dropping Growth Potential (Motley Fool) +8.43%
Feb-07-24 10:00AM	Cathie Wood Just Bought These 3 Biotech Stocks. Should You? (Motley Fool)
Jan-29-24 05:49PM	20 Countries With The Highest Life Expectancy in the World (Insider Monkey) +10.02%
Jan-28-24 08:45AM	2 Under-the-Radar Stocks With Incredible Upside Potential (Motley Fool)
Jan-27-24 01:04PM	Baillie Gifford Reduces Stake in Recursion Pharmaceuticals Inc (GuruFocus.com)
Jan-25-24 11:52PM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares (GuruFocus.com)
11:55AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought This Week (Motley Fool)
Jan-24-24 09:00AM	Altitude Lab Startups Raise Over $120M in Capital (GlobeNewswire)
Jan-18-24 09:01PM	Recursion Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-15-24 08:45AM	3 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Jan-13-24 05:20AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week (Motley Fool)
Jan-12-24 06:11AM	Recursions Chris Gibson on AI in biotech and virtuous cycles (BioPharma Dive)
Jan-11-24 01:11PM	40 Cities with the Lowest Life Expectancy in the US (Insider Monkey) -9.93%
Jan-09-24 02:16PM	Cathie Wood Is Betting Big on Recursion Pharmaceuticals (RXRX) Stock (InvestorPlace) +6.26%
Jan-08-24 10:59AM	Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference (GlobeNewswire) +5.70%
08:23AM	Recursion Pharmaceuticals (RXRX) Soars 7.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-04-24 07:59AM	Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline (GlobeNewswire) +14.65%
Jan-03-24 11:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought in 2024 (Motley Fool)
08:00AM	Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8 (GlobeNewswire)
Jan-02-24 01:57PM	3 Biotech Stocks at the Forefront of the Quest for Eternal Youth (InvestorPlace)
Dec-29-23 07:02PM	Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares (GuruFocus.com) -7.07%
Dec-22-23 06:22AM	40 Cities with the Highest Life Expectancy in the US (Insider Monkey)
Dec-20-23 07:59AM	Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry (GlobeNewswire) -5.78%
Dec-19-23 12:44PM	3 Genomics Stocks to Unlock the Future of Medicine (InvestorPlace) +6.24%
Dec-17-23 11:30AM	2 Cathie Wood Stocks That Might Be Smart Buys Right Now (Motley Fool)
Dec-16-23 01:00PM	AI Meets Biotech: 3 Top Stocks Transforming Medical Science (InvestorPlace)
Dec-15-23 03:06AM	Insider Sell: CFO Michael Secora Sells 50,000 Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com)
Dec-14-23 02:31PM	Recursion Pharmaceuticals Stock (NASDAQ:RXRX): Small Company, Big Future (TipRanks) +14.41%
Dec-09-23 11:06AM	Insider Sell: CEO Christopher Gibson Disposes of 59,829 Shares of Recursion Pharmaceuticals Inc ... (GuruFocus.com)
Nov-28-23 10:36AM	Cathie Wood picks up nearly 2 million shares of struggling, cheap stock (TheStreet.com) +7.50%
Nov-26-23 09:30AM	Recursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters. (Motley Fool)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Borgeson Blake	Director	May 14 '24	Sale	10.12	20,054	202,934	7,198,360	May 16 04:35 PM
Gibson Christopher	Chief Executive Officer	May 02 '24	Sale	8.47	50,000	423,500	834,820	May 03 06:24 PM
Gibson Christopher	Chief Executive Officer	May 01 '24	Sale	7.73	50,000	386,500	863,524	May 03 06:24 PM
Borgeson Blake	Director	Apr 30 '24	Sale	7.95	11,447	90,964	7,218,414	May 02 05:41 PM
Marriott Tina	President and COO	Apr 25 '24	Option Exercise	1.06	3,000	3,180	546,231	Apr 29 06:41 PM
Marriott Tina	President and COO	Apr 25 '24	Sale	7.67	3,000	23,020	543,231	Apr 29 06:41 PM
Secora Michael	Chief Financial Officer	Apr 17 '24	Option Exercise	2.22	37,500	83,250	1,254,179	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 17 '24	Sale	7.58	23,124	175,349	1,231,055	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 16 '24	Option Exercise	2.22	37,500	83,250	1,241,679	Apr 18 05:12 PM
Secora Michael	Chief Financial Officer	Apr 16 '24	Sale	7.67	25,000	191,658	1,216,679	Apr 18 05:12 PM
Borgeson Blake	Director	Apr 16 '24	Sale	7.66	11,447	87,725	7,229,861	Apr 18 05:12 PM
Gibson Christopher	Chief Executive Officer	Apr 04 '24	Sale	9.02	40,000	360,800	938,524	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 04 '24	Sale	9.02	25,000	225,500	0	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 03 '24	Sale	8.84	40,000	353,600	978,524	Apr 05 05:44 PM
Gibson Christopher	Chief Executive Officer	Apr 03 '24	Sale	8.84	25,000	221,000	0	Apr 05 05:44 PM
Borgeson Blake	Director	Apr 02 '24	Sale	8.82	11,447	100,942	7,241,308	Apr 03 05:42 PM
Gibson Christopher	Chief Executive Officer	Mar 28 '24	Sale	10.10	40,000	404,000	1,043,524	Apr 01 06:40 PM
Gibson Christopher	Chief Executive Officer	Mar 28 '24	Sale	10.10	25,000	252,500	0	Apr 01 06:40 PM
Marriott Tina	President and COO	Mar 21 '24	Option Exercise	1.06	8,000	8,480	647,982	Mar 25 06:39 PM
Marriott Tina	President and COO	Mar 21 '24	Sale	10.75	8,000	85,980	639,982	Mar 25 06:39 PM
Borgeson Blake	Director	Mar 19 '24	Sale	10.79	20,054	216,423	7,252,755	Mar 21 05:38 PM
Secora Michael	Chief Financial Officer	Mar 13 '24	Option Exercise	2.22	37,500	83,250	1,229,179	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 13 '24	Sale	11.03	25,000	275,815	1,204,179	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 12 '24	Option Exercise	2.22	37,500	83,250	1,216,679	Mar 14 07:28 PM
Secora Michael	Chief Financial Officer	Mar 12 '24	Sale	10.46	25,000	261,375	1,191,679	Mar 14 07:28 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Option Exercise	4.42	39,924	176,384	1,144,843	Mar 08 07:08 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Sale	11.86	36,319	430,682	1,108,524	Mar 08 07:08 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '24	Sale	11.55	25,000	288,823	0	Mar 08 07:08 PM
Borgeson Blake	Director	Mar 05 '24	Sale	12.06	20,054	241,805	7,272,809	Mar 07 06:53 PM
Marriott Tina	President and COO	Feb 22 '24	Option Exercise	1.06	8,000	8,480	647,982	Feb 23 07:22 PM
Marriott Tina	President and COO	Feb 22 '24	Sale	14.89	8,000	119,160	639,982	Feb 23 07:22 PM
Borgeson Blake	Director	Feb 20 '24	Sale	12.32	20,054	247,125	7,292,863	Feb 21 05:37 PM
Secora Michael	Chief Financial Officer	Feb 14 '24	Option Exercise	2.22	37,500	83,250	1,211,351	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 14 '24	Sale	10.46	25,000	261,425	1,186,351	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 13 '24	Option Exercise	2.22	37,500	83,250	1,198,851	Feb 15 06:00 PM
Secora Michael	Chief Financial Officer	Feb 13 '24	Sale	9.86	25,000	246,560	1,173,851	Feb 15 06:00 PM
Gibson Christopher	Chief Executive Officer	Feb 07 '24	Option Exercise	2.48	31,250	77,500	822,975	Feb 09 05:34 PM
Gibson Christopher	Chief Executive Officer	Feb 07 '24	Sale	9.22	48,272	444,981	774,703	Feb 09 05:34 PM
Borgeson Blake	Director	Feb 06 '24	Sale	9.30	11,447	106,489	7,312,917	Feb 08 06:54 PM
Larson Tina Marriott	President and COO	Jan 25 '24	Option Exercise	1.06	8,000	8,480	422,584	Jan 29 06:52 PM
Larson Tina Marriott	President and COO	Jan 25 '24	Sale	10.35	8,000	82,762	414,548	Jan 29 06:52 PM
Borgeson Blake	Director	Jan 23 '24	Sale	10.58	20,054	212,083	7,324,364	Jan 25 06:13 PM
Secora Michael	Chief Financial Officer	Jan 17 '24	Option Exercise	2.22	37,500	83,250	1,006,014	Jan 18 06:37 PM
Secora Michael	Chief Financial Officer	Jan 17 '24	Sale	10.25	25,000	256,348	981,014	Jan 18 06:37 PM
Secora Michael	Chief Financial Officer	Jan 16 '24	Option Exercise	2.22	37,500	83,250	993,514	Jan 18 06:37 PM
Virani Shafique	Chief Business Officer	Jan 16 '24	Option Exercise	2.22	18,000	39,960	154,748	Jan 18 06:39 PM
Secora Michael	Chief Financial Officer	Jan 16 '24	Sale	10.45	25,000	261,160	968,514	Jan 18 06:37 PM
Virani Shafique	Chief Business Officer	Jan 16 '24	Sale	10.93	18,000	196,740	136,748	Jan 18 06:39 PM
Li Dean Y	Director	Jan 09 '24	Sale	13.66	29,000	396,214	421,000	Jan 11 06:51 PM
Borgeson Blake	Director	Jan 09 '24	Sale	13.62	20,054	273,202	7,344,418	Jan 11 06:50 PM
Gibson Christopher	Chief Executive Officer	Jan 03 '24	Option Exercise	2.48	31,250	77,500	822,578	Jan 05 08:03 PM
Gibson Christopher	Chief Executive Officer	Jan 03 '24	Sale	9.49	30,853	292,804	791,725	Jan 05 08:03 PM
Gibson Christopher	Chief Executive Officer	Jan 03 '24	Sale	9.51	25,000	237,763	0	Jan 05 08:03 PM
Larson Tina Marriott	President and COO	Dec 28 '23	Option Exercise	1.06	8,000	8,480	422,548	Jan 02 04:58 PM
Larson Tina Marriott	President and COO	Dec 28 '23	Sale	10.58	8,000	84,654	414,548	Jan 02 04:58 PM
Borgeson Blake	Director	Dec 26 '23	Sale	10.63	20,054	213,144	7,364,472	Dec 28 05:48 PM
Virani Shafique	Chief Business Officer	Dec 15 '23	Option Exercise	2.22	18,000	39,960	154,748	Dec 19 07:22 PM
Virani Shafique	Chief Business Officer	Dec 15 '23	Sale	9.60	18,000	172,800	136,748	Dec 19 07:22 PM
Dar Zavain	Director	Dec 14 '23	Sale	9.00	20,141	181,269	53,823	Dec 18 06:44 PM
Secora Michael	Chief Financial Officer	Dec 13 '23	Option Exercise	2.22	37,500	83,250	981,014	Dec 14 06:53 PM
Secora Michael	Chief Financial Officer	Dec 13 '23	Sale	7.59	25,000	189,770	956,014	Dec 14 06:53 PM
Secora Michael	Chief Financial Officer	Dec 12 '23	Option Exercise	2.22	37,500	83,250	968,514	Dec 14 06:53 PM
Secora Michael	Chief Financial Officer	Dec 12 '23	Sale	7.39	25,000	184,868	943,514	Dec 14 06:53 PM
Borgeson Blake	Director	Dec 12 '23	Sale	7.40	11,447	84,693	7,384,526	Dec 14 06:51 PM
Gibson Christopher	Chief Executive Officer	Dec 06 '23	Option Exercise	2.48	31,250	77,500	851,157	Dec 08 05:22 PM
Gibson Christopher	Chief Executive Officer	Dec 06 '23	Sale	7.49	59,829	448,394	791,328	Dec 08 05:22 PM
Borgeson Blake	Director	Nov 28 '23	Sale	6.72	11,447	76,918	7,395,973	Nov 30 05:41 PM
Larson Tina Marriott	President and COO	Nov 16 '23	Option Exercise	1.06	3,000	3,180	416,404	Nov 17 05:53 PM
Larson Tina Marriott	President and COO	Nov 16 '23	Sale	6.76	3,000	20,280	413,404	Nov 17 05:53 PM
Secora Michael	Chief Financial Officer	Nov 15 '23	Option Exercise	2.22	37,500	83,250	963,186	Nov 16 06:54 PM
Virani Shafique	Chief Business Officer	Nov 15 '23	Option Exercise	2.22	18,000	39,960	158,351	Nov 17 05:52 PM
Secora Michael	Chief Financial Officer	Nov 15 '23	Sale	7.32	25,000	182,986	938,186	Nov 16 06:54 PM
Virani Shafique	Chief Business Officer	Nov 15 '23	Sale	6.51	18,000	117,180	140,351	Nov 17 05:52 PM
Secora Michael	Chief Financial Officer	Nov 14 '23	Option Exercise	2.22	37,500	83,250	950,686	Nov 16 06:54 PM
Secora Michael	Chief Financial Officer	Nov 14 '23	Sale	6.32	25,000	157,942	925,686	Nov 16 06:54 PM
Borgeson Blake	Director	Nov 14 '23	Sale	6.32	8,885	56,151	7,407,420	Nov 16 06:55 PM
Gibson Christopher	Chief Executive Officer	Nov 01 '23	Option Exercise	2.48	31,250	77,500	873,997	Nov 03 06:14 PM
Gibson Christopher	Chief Executive Officer	Nov 01 '23	Sale	5.20	37,177	193,306	836,820	Nov 03 06:14 PM
Gibson Christopher	Chief Executive Officer	Nov 01 '23	Sale	5.12	25,000	127,995	0	Nov 03 06:14 PM
Borgeson Blake	Director	Oct 31 '23	Sale	5.27	8,885	46,864	7,416,305	Nov 02 07:02 PM
Larson Tina Marriott	President and COO	Oct 26 '23	Option Exercise	1.06	3,000	3,180	421,782	Oct 30 06:26 PM
Larson Tina Marriott	President and COO	Oct 26 '23	Sale	5.63	3,000	16,885	418,782	Oct 30 06:26 PM
Borgeson Blake	Director	Oct 17 '23	Sale	6.58	8,885	58,483	7,425,190	Oct 19 05:34 PM
Virani Shafique	Chief Business Officer	Oct 16 '23	Option Exercise	2.22	18,000	39,960	158,351	Oct 18 05:34 PM
Virani Shafique	Chief Business Officer	Oct 16 '23	Sale	6.30	18,000	113,400	140,351	Oct 18 05:34 PM
Secora Michael	Chief Financial Officer	Oct 11 '23	Option Exercise	2.22	37,500	83,250	938,186	Oct 12 06:07 PM
Secora Michael	Chief Financial Officer	Oct 11 '23	Sale	6.85	25,000	171,312	913,186	Oct 12 06:07 PM
Secora Michael	Chief Financial Officer	Oct 10 '23	Option Exercise	2.22	37,500	83,250	925,686	Oct 12 06:07 PM
Secora Michael	Chief Financial Officer	Oct 10 '23	Sale	7.07	25,000	176,762	900,686	Oct 12 06:07 PM
Gibson Christopher	Chief Executive Officer	Oct 04 '23	Option Exercise	2.48	31,250	77,500	902,541	Oct 06 06:12 PM
Gibson Christopher	Chief Executive Officer	Oct 04 '23	Sale	7.21	59,794	431,025	842,747	Oct 06 06:12 PM
Borgeson Blake	Director	Oct 03 '23	Sale	7.29	8,885	64,778	7,434,075	Oct 05 06:25 PM
Larson Tina Marriott	President and COO	Sep 28 '23	Option Exercise	1.06	3,000	3,180	421,782	Oct 02 06:19 PM
Larson Tina Marriott	President and COO	Sep 28 '23	Sale	7.72	3,000	23,159	418,782	Oct 02 06:19 PM
Borgeson Blake	Director	Sep 19 '23	Sale	8.36	8,885	74,278	7,442,960	Sep 21 06:35 PM
Virani Shafique	Chief Business Officer	Sep 15 '23	Option Exercise	2.22	18,000	39,960	158,351	Sep 19 05:50 PM
Virani Shafique	Chief Business Officer	Sep 15 '23	Sale	8.66	18,000	155,880	140,351	Sep 19 05:50 PM
Secora Michael	Chief Financial Officer	Sep 13 '23	Option Exercise	2.22	37,500	83,250	913,186	Sep 14 06:26 PM
Secora Michael	Chief Financial Officer	Sep 13 '23	Sale	8.69	25,000	217,318	888,186	Sep 14 06:26 PM
Secora Michael	Chief Financial Officer	Sep 12 '23	Option Exercise	2.22	37,500	83,250	900,686	Sep 14 06:26 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

MRK

Merck & Co Inc

RXRX

Recursion Pharmaceuticals Inc

Upgrade your FINVIZ experience